Author:
Uehara Yuki,Suzukawa Maho,Horie Masafumi,Igarashi Sayaka,Minegishi Masaaki,Takada Kazufumi,Saito Akira,Nagase Hiroyuki
Reference37 articles.
1. Asthma;Porsbjerg;Lancet (london, England),2023
2. T-helper cell type-2 regulation in allergic disease;Georas;Eur. Respir. J.,2005
3. Biologic Therapies for Severe Asthma;Brusselle;N. Engl. J. Med.,2022
4. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma;Busse;J. Allergy Clin. Immunol.,2001
5. E.R. Bleecker, J.M. FitzGerald, P. Chanez, A. Papi, S.F. Weinstein, P. Barker, S. Sproule, G. Gilmartin, M. Aurivillius, V. Werkstrom, M. Goldman, S.s. investigators, Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial, Lancet (London, England), 388 (2016) 2115-2127.